News stories about CVS Health Corporation (NYSE:CVS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CVS Health Corporation earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the pharmacy operator an impact score of 45.9459918571196 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- CVS Health Corporation (CVS) Short Interest Up 16.1% in October (americanbankingnews.com)
- Drug Costs in the Spotlight With Trump’s Pick for Health Secretary (bloomberg.com)
- Indiana Added to CVS Apprenticeship Program (insideindianabusiness.com)
- Kiltearn Partners LLP Buys CVS Health Corp, General Electric Co, United Natural Foods Inc, … (nasdaq.com)
- Amazon Will Not Store or Ship Drugs: Report (finance.yahoo.com)
Several brokerages have issued reports on CVS. BidaskClub upgraded CVS Health Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. Citigroup Inc. lowered their price target on CVS Health Corporation from $88.00 to $87.00 and set a “neutral” rating for the company in a report on Thursday, August 17th. Royal Bank Of Canada began coverage on CVS Health Corporation in a report on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 price target for the company. Jefferies Group LLC increased their price target on CVS Health Corporation from $82.00 to $86.00 and gave the stock a “hold” rating in a report on Friday, September 15th. Finally, Wolfe Research downgraded CVS Health Corporation from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $89.00 to $82.00 in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. CVS Health Corporation currently has an average rating of “Buy” and an average price target of $85.82.
CVS Health Corporation (CVS) opened at $70.44 on Wednesday. CVS Health Corporation has a 52-week low of $66.45 and a 52-week high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $72,408.67, a P/E ratio of 12.52, a P/E/G ratio of 1.23 and a beta of 0.86.
CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the consensus estimate of $1.49 by $0.01. CVS Health Corporation had a return on equity of 16.96% and a net margin of 2.77%. The firm had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. During the same period in the prior year, the firm posted $1.64 earnings per share. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. equities analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, November 3rd. Investors of record on Tuesday, October 24th were given a dividend of $0.50 per share. The ex-dividend date was Monday, October 23rd. This represents a $2.00 annualized dividend and a yield of 2.84%. CVS Health Corporation’s dividend payout ratio (DPR) is presently 41.32%.
In other news, EVP Thomas M. Moriarty sold 90,267 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total value of $7,186,155.87. Following the completion of the sale, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO David M. Denton sold 237,078 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.65, for a total value of $18,883,262.70. Following the completion of the sale, the chief financial officer now directly owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders have sold 714,125 shares of company stock valued at $58,119,381 over the last three months. Insiders own 0.61% of the company’s stock.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.